---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-071530"
form_type: "8-K"
ticker: "OCUL"
cik: "0001393434"
company_name: "OCULAR THERAPEUTIX, INC"
filed_at: "2024-06-14T23:59:59+00:00"
generated_at: "2026-06-01T04:16:42.647774+00:00"
event_type: "other"
sentiment: "neutral"
materiality_score: 0.3
calibrated_materiality_score: 0.3
confidence: "high"
source: SEC EDGAR
---

# Ocular Therapeutix shareholders approve doubling authorized shares to 400M and increasing equity plan by 7M shares

## Summary
- Stockholders approved amendment to increase authorized common stock from 200M to 400M shares.
- Stockholders approved Amendment No. 3 to 2021 Stock Incentive Plan, adding 7M shares for issuance.
- Elected Adrienne L. Graves, Ph.D. and Charles Warden as Class I directors for term ending 2027.
- Ratified PricewaterhouseCoopers LLP as independent auditor for FY 2024; votes: 119.6M for, 0.86M against.
- Non-binding advisory vote on executive compensation passed with 76.3M for, 9.3M against.

## SEC filing metadata
- accession: 0001104659-24-071530
- form_type: 8-K
- ticker: OCUL
- cik: 0001393434
- company_name: OCULAR THERAPEUTIX, INC
- filed_at: 2024-06-14T23:59:59+00:00
- event_type: other
- sentiment: neutral
- materiality_score: 0.3
- calibrated_materiality_score: 0.3
- confidence: high
- sec_items: 5.02, 5.03, 5.07, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1393434/000110465924071530/0001104659-24-071530-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1393434/000110465924071530/tm2417152d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-071530
- JSON: https://secwatch.observer/filing/0001104659-24-071530.json
- Plain text: https://secwatch.observer/filing/0001104659-24-071530.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.